Smartleaf Asset Management
ACRS icon

Smartleaf Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

Smartleaf Asset Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.98K Hold
376
– – ﹤0.01% 3041
2026
Q2 		$1.89K Hold
376
– – ﹤0.01% 2967
2026
Q1 		$1.31K Hold
376
– – ﹤0.01% 3063
2025
Q4 		$1.09K Buy
+376
New +$950 ﹤0.01% 3148

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Decheng Capital
Decheng Capital Menlo Park, California $685M AUM 129.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JHC
Jones Hill Capital New York $589M AUM
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Smartleaf Asset Management's ACRS Position: Q3 2026 in Review

Smartleaf Asset Management held its Aclaris Therapeutics (ACRS) position steady in Q3 2026 at 376 shares worth $1.98K. The position accounts for ﹤0.01% of the portfolio, ranked #3041.

Smartleaf Asset Management first reported a position in ACRS in Q4 2025 and has held it in 4 quarters since. 111 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.

  • Smartleaf Asset Management held 376 shares of Aclaris Therapeutics worth $1.98K as of Q3 2026.
  • Smartleaf Asset Management left its Aclaris Therapeutics share count unchanged in Q3 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #3041 holding.
  • Smartleaf Asset Management first reported a position in Aclaris Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 111 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.